Skip to main content

Table 1 Patient, disease and treatment characteristics

From: First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer

 

Pt 1

Pt 2

Pt 3

Pt 4

Pt 5

Pt 6

Sex

F

M

M

F

M

F

Age at diagnosis

56

41

32

74

32

39

Year of diagnosis

2005

2013

2006

2016

2004

2017

Tumour type

AdCC

AdCC

AdCC

Adenocarcinoma NOS

Acinic cell carcinoma

AdCC

Tumour site

Hard palate

Parotid

Cheek mucosa

Parotid

Parotid

Submandibular gland

Treatment

Local excision

Local excision + radiotherapy

Local excision + radiotherapy

Palliative radiotherapy

Local excision + radiotherapy

Local excision + radiotherapy

Disease

Locoregional recurrence

Parapharyngeal, intracranial

Parapharyngeal, lymphatic

Distant metastases

Lung, Liver

-

Lung, Bone (vertebra)

Bone (skull, vertebra)

Lymphatic (inguinal), Lung, Bone (vertebra)

-

Completed ‘conventional’ palliative treatment

None

None

Chemotherapy (CAP), radiotherapy

Radiotherapy

Chemotherapy (CAP), radiotherapy

Chemotherapy (CAP), radiotherapy

PSMA expression on IHC (%)

5

30

N/A

30

95

30

SUVmax VOI before treatment

3.5 lung

6.5 intracranial

10.2 pelvis

12.5 pelvis

9.7 pelvis

7.0 parapharyngeal

Treatment

Diagnosis to 177Lu-PSMA (years)

12

6

12

1

14

2

No. cycles

4

4

2

1

2

2

SUVmax VOI after treatment

N/A

4.5

N/A

N/A

17.6

9.4

Reason of discontinuation

End of protocol

End of protocol

Disease progression, adverse effects

Demotivation due to side-effects

Disease progression

Disease progression

Side effects

Side effects (CTCAE grade)

Fatigue (2)

Dyspnoea (2)

Nausea (1)

Fatigue (1)

Nausea (1)

Vomiting (1)

Xerostomia (1)

Fatigue (1)

Bone pain (2)

Thrombocytopenia (3)

Fatigue (1)

Xerostomia (1)

Fatigue (1)

Xerostomia (1)

Bone pain (2)

Fatigue (1)

Xerostomia (2)

Response

Clinical

Less dyspnoea, less fatigue

Improved facial expression and sensibility, less fatigue

Disease progression

N/A

Significant pain relief (6 weeks)

Diminution of facial nerve palsy, pain relief

Radiological

Stable lung lesions, minimal progression of liver metastases

Stable disease, decrease SUVmax

Disease progression

N/A

Disease progression

Disease progression

Follow-up

(months after first treatment)

Deceased

(7)

Alive with disease

(36)

Deceased

(3)

Deceased

(5)

Deceased

(6)

Deceased

(9)

  1. AdCC: Adenoid cystic carcinoma; CAP: cyclophosphamide, adriamycin, cisplatin; PSMA: prostate-specific membrane antigen; IHC: immunohistochemistry; N/A: not available; CTCAE: common terminology criteria for adverse events